Hormonal
Pioglitazone administration reverses hyperglycemia and restores beta-cell maturity markers (increased insulin/Nkx6.1, decreased Aldh1a3) in diabetic db/db mice, while promoting a 'browning' gene expression profile (UCP-1, Cidea) in white adipose tissue.
Pioglitazone effectively lowers blood glucose and improves beta-cell function in insulin-resistant individuals, even if it causes some weight gain. This gain is largely subcutaneous and correlates with improved metabolic health. It also promotes 'browning' markers in fat tissue, suggesting enhanced metabolic flexibility.
Oral administration of pioglitazone lowered blood glucose levels in db/db mice... pancreatic β-cells from db/db mice treated with pioglitazone had greater expression of insulin and Nkx6.1 as well as reduced abundance of the de-differentiation marker Aldh1a3... white adipose tissue from db/db mice... displayed increased expression of UCP-1, a marker typically associated with brown adipose tissue.
Why this rating
High-quality mechanistic data in a robust animal model (db/db) with translational human adipose tissue data, but lacks direct human clinical efficacy endpoints (e.g., HbA1c reduction) in this specific text.
Source
Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans
J. Jason Collier et al. · Biomedicines · 2021
DOI 10.3390/biomedicines9091189
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →